Association of an UCP4 (SLC25A27) haplotype with ultra-resistant schizophrenia

Pharmacogenomics

Volumn 12, Issue 2, 2011, Pages 185-193

  Mouaffak, Fayçal ^b   Kebir, Oussama ^b   Bellon, Alfredo ^b   Gourevitch, Raphael ^b   Tordjman, Sylvie ^b   Viala, Annie ^b   Millet, Bruno ^b   Jaafari, Nematollah ^b   Olié, Jean Pierre ^b   Krebs, Marie Odile ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b NONE

Author keywords

antipsychotic; association study; polymorphism; psychosis; tag SNP; treatment resistance

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN; UNCOUPLING PROTEIN 2; UNCOUPLING PROTEIN 4; UNCOUPLING PROTEIN 5;

3' UNTRANSLATED REGION; ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CAUCASIAN; CLINICAL ASSESSMENT TOOL; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DRUG RESPONSE; EXON; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; GLOBAL ASSESSMENT OF FUNCTIONING; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; POSITIVE AND NEGATIVE SYNDROME SCALE; REMISSION; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; DRUG RESISTANCE; FEMALE; FRANCE; GENOME-WIDE ASSOCIATION STUDY; HAPLOTYPES; HUMANS; ION CHANNELS; MALE; MEMBRANE TRANSPORT PROTEINS; MITOCHONDRIAL PROTEINS; NERVE TISSUE PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 79951935677     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.179     Document Type: Article

References (64)

1. Saha S, Chant D, Welham J, Mcgrath J: A systematic review of the prevalence of schizophrenia. PLoS Med. 2(5), e141 (2005).
2. Murray CJ, Lopez AD: Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 349(9063), 1436-1442 (1997).
3. Lewis DA, Levitt P: Schizophrenia as a disorder of neurodevelopment. Annu. Rev. Neurosci. 25, 409-432 (2002).
4. Marenco S, Weinberger DR: The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave. Dev. Psychopathol. 12(3), 501-527 (2000).
5. Rapoport JL, Addington AM, Frangou S, Psych MR: The neurodevelopmental model of schizophrenia: update 2005. Mol. Psychiatry 10(5), 434-449 (2005).
6. Weinberger DR, Mcclure RK: Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain? Arch. Gen. Psychiatry 59(6), 553-558 (2002).
7. Mccullumsmith RE, Clinton SM, Meador-Woodruff JH: Schizophrenia as a disorder of neuroplasticity. Int. Rev. Neurobiol. 59, 19-45 (2004).
8. Conley RR, Kelly DL: Management of treatment resistance in schizophrenia. Biol. Psychiatry 50(11), 898-911 (2001).
9. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45(9), 789-796 (1988).
10. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B: Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry 158(4), 518-526 (2001).
11. Rosenheck R, Cramer J, Xu W et al.: A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of veterans affairs cooperative study group on clozapine in refractory schizophrenia. N. Engl. J. Med. 337(12), 809-815 (1997).
12. Wahlbeck K, Cheine M, Essali A, Adams C: Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am. J. Psychiatry 156(7), 990-999 (1999).
13. Buckley P, Miller A, Olsen J, Garver D, Miller DD, Csernansky J: When symptoms persist: clozapine augmentation strategies. Schizophr. Bull. 27(4), 615-628 (2001).
14. Elkis H: Treatment-resistant schizophrenia. Psychiatr. Clin. North Am. 30(3), 511-533 (2007).
15. Mouaffak F, Tranulis C, Gourevitch R et al.: Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. Clin. Neuropharmacol. 29(1), 28-33 (2006). Proposes an operational definition of schizophrenia refractory to clozapine ('ultra-resistant schizophrenia') for the implementation and homogenization of future therapeutic trials.
16. Harrison PJ, Weinberger DR: Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry 10(1), 40-68, image 45 (2005).
17. Macdonald ML, Eaton ME, Dudman JT, Konradi C: Antipsychotic drugs elevate mRNA levels of presynaptic proteins in the frontal cortex of the rat. Biol. Psychiatry 57(9), 1041-1051 (2005).
18. Matsumoto M, Shikanai H, Togashi H et al.: Characterization of clozapine-induced changes in synaptic plasticity in the hippocampal-MPCF pathway of anesthetized rats. Brain Res. 1195, 50-55 (2008).
19. Arranz MJ, De Leon J: Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol. Psychiatry 12(8), 707-747 (2007). Summarizes the key findings from the last decade of research in pharmcogenetics and pharmacogenomics of schizophrenia.
20. Hagberg H: Mitochondrial impairment in the developing brain after hypoxia-ischemia. J. Bioenerg. Biomembr. 36(4), 369-373 (2004).
21. Krebs MO, Bellon A, Mainguy G, Jay TM, Frieling H: One-carbon metabolism and schizophrenia: current challenges and future directions. Trends Mol. Med. 15(12), 562-570 (2009). Discusses the potential roles of one-carbon metabolism in the pathophysiology of schizophrenia.
22. Prabakaran S, Swatton JE, Ryan MM et al.: Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry 9(7), 684-697, 643 (2004). Proposes that oxidative stress and the ensuing cellular adaptations are linked to the schizophrenia disease process.
23. Uranova NA, Orlovskaia DD, Vikhreva OV, Zimina IS, Rakhmanova VI: [Morphometric study of ultrastructural changes in oligodendroglial cells in the postmortem brain in endogenous psychoses]. Vestn. Ross. Akad. Med Nauk (7), 42-48 (2001).
24. Kung L, Roberts RC: Mitochondrial pathology in human schizophrenic striatum: a postmortem ultrastructural study. Synapse 31(1), 67-75 (1999).
25. Kolomeets NS: [The role of microglia reactivity in the cerebral pathology in schizophrenia]. Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova 109(3), 60-63 (2009).
26. Regenold WT, Phatak P, Marano CM, Sassan A, Conley RR, Kling MA: Elevated cerebrospinal fluid lactate concentrations in patients with bipolar disorder and schizophrenia: implications for the mitochondrial dysfunction hypothesis. Biol. Psychiatry 65(6), 489-494 (2009).
27. Kroemer G, Reed JC: Mitochondrial control of cell death. Nat. Med. 6(5), 513-519 (2000).
28. Nicholls DG, Ward MW: Mitochondrial membrane potential and neuronal glutamate excitotoxicity: mortality and millivolts. Trends Neurosci. 23(4), 166-174 (2000).
29. Andrews ZB, Diano S, Horvath TL: Mitochondrial uncoupling proteins in the CNS: in support of function and survival. Nat. Rev. Neurosci. 6(11), 829-840 (2005). Presents data on the regulation and function of neuronal uncoupling proteins.
30. Mao W, Yu XX, Zhong A et al.: UCP4, a novel brain-specific mitochondrial protein that reduces membrane potential in mammalian cells. FEBS Lett. 443(3), 326-330 (1999).
31. Sanchis D, Fleury C, Chomiki N et al.: Bmcp1, a novel mitochondrial carrier with high expression in the central nervous system of humans and rodents, and respiration uncoupling activity in recombinant yeast. J. Biol. Chem. 273(51), 34611-34615 (1998).
32. Fleury C, Neverova M, Collins S et al.: Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. Nat. Genet. 15(3), 269-272 (1997).
33. Diano S, Matthews RT, Patrylo P et al.: Uncoupling protein 2 prevents neuronal death including that occurring during seizures: a mechanism for preconditioning. Endocrinology 144(11), 5014-5021 (2003).
34. Chu AC, Ho PW, Kwok KH et al.: Mitochondrial UCP4 attenuates MPP+ - and dopamine-induced oxidative stress, mitochondrial depolarization, and ATP deficiency in neurons and is interlinked with ucp2 expression. Free Radic. Biol. Med. 46(6), 810-820 (2009).
35. Ho PW, Chu AC, Kwok KH, Kung MH, Ramsden DB, Ho SL: Knockdown of uncoupling protein-5 in neuronal SH-SY5Y cells: Effects on MPP+-induced mitochondrial membrane depolarization, ATP deficiency, and oxidative cytotoxicity. J. Neurosci. Res. 84(6), 1358-1366 (2006).
36. Chan SL, Liu D, Kyriazis GA, Bagsiyao P, Ouyang X, Mattson MP: Mitochondrial uncoupling protein-4 regulates calcium homeostasis and sensitivity to store depletion-induced apoptosis in neural cells. J. Biol. Chem. 281(49), 37391-37403 (2006).
37. + uniport. Nat. Cell Biol. 9(4), 445-452 (2007).
38. Ben-Shachar D, Laifenfeld D: Mitochondria, synaptic plasticity, and schizophrenia. Int. Rev. Neurobiol. 59, 273-296 (2004). Proposes that mitochondrial dysfunction in schizophrenia could cause, or arise from, anomalies in processes of plasticity.
39. Ng F, Berk M, Dean O, Bush AI: Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int. J. Neuropsychopharmacol. 11(6), 851-876 (2008). Proposes that oxidative mechanisms may form unifying common pathogenic pathways in psychiatric disorders.
40. Yu WY, Chang HW, Lin CH, Cho CL: Short telomeres in patients with chronic schizophrenia who show a poor response to treatment. J. Psychiatry Neurosci. 33(3), 244-247 (2008). Oxidative stress, whose marker is shortened telomere, and the ensuing cellular dysfunction may be a factor contributing to the deterioration in treatment-resistant schizophrenia.
41. Nishioka N, Arnold SE: Evidence for oxidative DNA damage in the hippocampus of elderly patients with chronic schizophrenia. Am. J. Geriatr. Psychiatry 12(2), 167-175 (2004).
42. Yasuno K, Ando S, Misumi S et al.: Synergistic association of mitochondrial uncoupling protein (UCP) genes with schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B(2), 250-253 (2007). First report of an association between schizophrenia and neuronal uncoupling proteins.
43. Nurnberger JI Jr, Blehar MC, Kaufmann CA et al.: Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH genetics initiative. Arch. Gen. Psychiatry 51(11), 849-859; discussion 863-844 (1994).
44. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, DSM-IV, (4th Edition). American Psychiatric Association, Washington, DC, USA (1994).
45. Ventura J, Lukoff D, Nuechterlein KH, Liberman RP, Green MFS, Shaner A: Manual for the expanded Brief Psychiatic Rating Scale. Int. J. Methods Psych. Res. 3, 227-244 (1993).
46. Ventura J, Green MF, Shaner A, Lieberman RP: Training and quality assurance with the Brief Psychiatic Rating Scale: the drift busters. Int. J. Methods Psychiatr. Res. 3, 221-244 (1993).
47. Mouaffak F, Morvan Y, Bannour S et al.: Validation of the French version of the expanded Brief Psychiatic Rating Scale with anchor BPRS-E(A). Encephale 36(4), 294-301 (2009).
48. Guy W (Ed.): Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology, Revised. Department of Health, Education and Welfare, MD, USA, 218-222 (1976).
49. Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13(2), 261-276 (1987).
50. Overall JE, Gorham DR: The Brief Psychiatic Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol. Bull. 24, 97-99 (1988).
51. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2), 263-265 (2005).
52. Gabriel SB, Schaffner SF, Nguyen H et al.: The structure of haplotype blocks in the human genome. Science 296(5576), 2225-2229 (2002).
53. Cipriani A, Boso M, Barbui C: Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst. Rev. (3), CD006324 (2009).
54. Barbui C, Signoretti A, Mule S, Boso M, Cipriani A: Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr. Bull. 35(2), 458-468 (2009).
55. Taylor DM, Smith L: Augmentation of clozapine with a second antipsychotic - a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatr. Scand. 119(6), 419-425 (2009).
56. Szolnoki Z, Kondacs A, Mandi Y, Bodor A, Somogyvari F: A homozygous genetic variant of mitochondrial uncoupling protein 4 exerts protection against the occurrence of multiple sclerosis. Neuromolecular Med. 11(2), 101-105 (2009).
57. Feinstein A, Du Boulay G, Ron MA: Psychotic illness in multiple sclerosis. A clinical and magnetic resonance imaging study. Br. J. Psychiatry 161, 680-685 (1992).
58. Smorodchenko A, Rupprecht A, Sarilova I et al.: Comparative analysis of uncoupling protein 4 distribution in various tissues under physiological conditions and during development. Biochim. Biophys. Acta 1788(10), 2309-2319 (2009). Provides data on the developmental expression pattern of UCP4.
59. Mattson MP: Brain evolution and lifespan regulation: Conservation of signal transduction pathways that regulate energy metabolism. Mech. Ageing Dev. 123(8), 947-953 (2002).
60. Mattson MP, Liu D: Mitochondrial potassium channels and uncoupling proteins in synaptic plasticity and neuronal cell death. Biochem. Biophys. Res. Commun. 304(3), 539-549 (2003).
61. Sahin E, Depinho RA: Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature 464(7288), 520-528 (2010).
62. Passos JF, Saretzki G, Ahmed S et al.: Mitochondrial dysfunction accounts for the stochastic heterogeneity in telomere-dependent senescence. PLoS Biol. 5(5), e110 (2007).
63. Kao HT, Cawthon RM, Delisi LE et al.: Rapid telomere erosion in schizophrenia. Mol. Psychiatry 13(2), 118-119 (2008).
64. Ericson E, Gebbia M, Heisler LE et al.: Off-target effects of psychoactive drugs revealed by genome-wide assays in yeast. PLoS Genet. 4(8), e1000151 (2008). Proposes that mitochondrial reactive oxygen species is a major determinant of telomere-dependent senescence.